SCHEMBL2295321

SCHEMBL2295321

CCc1cc(OC)cc(OCC(N)=O)c1-c1nc2ccc(F)cn2c1Nc1c(C)cccc1Cl

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 9/20 0.39
MAPT P10636 7/20 0.39
TRPA1 O75762 1/20 0.38
TP53 P04637 3/20 0.35
THRB P10828 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
LMNA P02545 2/20 0.35
GLA P06280 1/20 0.35
RAB9A P51151 1/20 0.35
CHRNA7 P36544 2/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CNR2 P34972 1/20 0.34
FGFR4 P22455 1/20 0.33
LCK P06239 2/20 0.33
POLB P06746 1/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2287599 0.95 GAA (0.41) GAAMAPTTRPA1TP53THRB
SCHEMBL2295061 0.93 MAPT (0.40) GAAMAPTTRPA1TP53THRB
SCHEMBL2294986 0.93 TRPA1 (0.40) GAAMAPTTRPA1TP53SMN1; SMN2
SCHEMBL2293350 0.91 CNR2 (0.35) GAAMAPTTRPA1TP53THRB
SCHEMBL2289541 0.90 TRPA1 (0.41) GAAMAPTTRPA1TP53THRB
SCHEMBL2292332 0.90 TRPA1 (0.41) GAAMAPTTRPA1TP53SMN1; SMN2
SCHEMBL2287227 0.90 GAA (0.42) GAAMAPTTRPA1TP53THRB
SCHEMBL2290931 0.90 MAPT (0.38) GAAMAPTTRPA1TP53THRB
SCHEMBL2287002 0.90 TRPA1 (0.38) GAAMAPTTRPA1TP53SMN1; SMN2
SCHEMBL2290337 0.90 TRPA1 (0.41) GAAMAPTTRPA1TP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP claimed
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP disclosed
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 US disclosed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS GLP1R, SLC5A1, SLC5A2 GAA 1202/4885MAPT 1138/4885TRPA1 1229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.